The US DOJ reaches deferred prosecution agreement with pharma company fined a record criminal penalty for a domestic antitrust case (Sandoz)

Major Generic Pharmaceutical Company Admits to Antitrust Crimes: Sandoz Inc. Agrees to Pay a $195 Million Criminal Penalty, the Largest for a Domestic Antitrust Case* Sandoz Inc., a generic pharmaceutical company headquartered in New Jersey, was charged for conspiring to allocate customers, rig bids, and fix prices for generic drugs, the Department of Justice announced. A four-count felony charge was filed today in the United States District Court for the Eastern District of Pennsylvania in Philadelphia, charging Sandoz with participating in four criminal antitrust conspiracies, each with a competing manufacturer of generic drugs and various individuals. This represents the third pharmaceutical company to admit to criminal antitrust charges in the Antitrust Division’s ongoing

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

US Department of Justice Antitrust Division, The US DOJ reaches deferred prosecution agreement with pharma company fined a record criminal penalty for a domestic antitrust case (Sandoz), 2 March 2020, e-Competitions March 2020, Art. N° 93648

Visites 192

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues